Note: This document contains side effect information about diltiazem. Some of the dosage forms listed on this page may not apply to the brand name Matzim LA.
More frequent side effects include: dizziness, edema, asthenia, headache, and vasodilation. See below for a comprehensive list of adverse effects.
Applies to diltiazem: oral capsule extended release, oral capsule extended release 12 hr, oral capsule extended release 24 hr, oral tablet, oral tablet extended release, oral tablet extended release 24 hr
Other dosage forms:
Along with its needed effects, diltiazem (the active ingredient contained in Matzim LA) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking diltiazem:
Incidence not known
Some side effects of diltiazem may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to diltiazem: compounding powder, intravenous powder for injection, intravenous solution, oral capsule extended release, oral tablet, oral tablet extended release
The most commonly reported side effects include edema, headache, and dizziness.
Very common (10% or more): Peripheral edema (up to 15%)
Common (1% to 10%): Arrhythmia (junctional rhythm/isorhythmic dissociation), asymptomatic/symptomatic hypotension, atrioventricular (AV) block (first/second/third degree), bradycardia, bundle branch block, ECG abnormality, edema, extrasystole/ventricular extrasystole, flushing, lower limb edema, palpitations, vasodilation
Uncommon (0.1% to 1%): Orthostatic hypotension
Frequency not reported: Angina, asystole/cardiac arrest, atrial flutter, chest pain, development/aggravation of congestive heart failure, hypotension, sinoatrial block, sinus node dysfunction, sinus pause/arrest, vasculitis, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia/tachycardia
Postmarketing reports: Myocardial infarction, vasodilation symptoms (flushing, lower limb edema, sweating)
A patient with Prinzmetal's angina developed asystole after a single, 60 mg dose.
Myocardial infarction was not readily distinguishable from the natural history of the disease.
Vasodilatory events (e.g., peripheral edema, headache, flushing) are dose-related and may be more common in elderly patients.
First degree AV block and sinus bradycardia occurred more frequently with higher doses.
Common (1% to 10%): Asthenia, fatigue, flu syndrome, infection, malaise, pain
Frequency not reported: Thirst, tinnitus
Common (1% to 10%): Abdominal enlargement, constipation, dyspepsia, gastric pain, nausea
Uncommon (0.1% to 1%): Diarrhea, vomiting
Rare (0.01% to 0.1%): Dry mouth
Frequency not reported: Gastrointestinal disorder, gingivitis, gingival hyperplasia
Well-documented cases of rashes (as leukocytoclastic vasculitis) have been reported, but a definitive between these events and this drug have not been established.
Lichenoid keratosis and hyperpigmentation occurred in skin exposed to the sun.
Common (1% to 10%): Erythema, hot flushes, rash, urticaria
Frequency not reported: Acute generalized exanthematous pustular dermatitis, desquamative erythema with/without fever exfoliative dermatitis, facial edema, hyperhidrosis/sweating, hyperpigmentation, leukocytoclastic vasculitis, petechiae, photosensitivity (lichenoid keratosis), pruritus, Steven-Johnson's syndrome
Postmarketing reports: Allergic dermatitis, alopecia, angioneurotic edema, erythema multiforme, generalized dermatitis, musculocutaneous reactions, simple erythema, toxic epidermal necrolysis
Common (1% to 10%): Bronchitis, cough, increased cough, pharyngitis, sinus/nasal congestion
Frequency not reported: Dyspnea, epistaxis
Postmarketing reports: Asthma aggravation, bronchospasm
Common (1% to 10%): Dizziness, headache, lightheadedness
Frequency not reported: Amnesia, dysgeusia, extrapyramidal syndrome/symptoms, gait abnormality, paresthesia, somnolence, syncope, tremor
Dizziness occurred more frequently with higher doses.
Common (1% to 10%): Myalgia
Frequency not reported: Creatine phosphokinase (CPK) increase, muscle cramp, muscle pain, muscle weakness, myopathy, neck rigidity, osteoarticular pain
Common (1% to 10%): Gout
Frequency not reported: Anorexia, hyperglycemia, hyperuricemia, mild elevation of alkaline phosphatase, mild elevation of lactate dehydrogenase, thirst, weight increase
Common (1% to 10%): Impotence
Frequency not reported: Albuminuria, crystalluria, nocturia, polyuria, sexual difficulties
Common (1% to 10%): Conjunctivitis
Frequency not reported: Amblyopia, eye irritation, periorbital edema, retinopathy
Common (1% to 10%): Injection site reactions (e.g., itching, burning)
Uncommon (0.1% to 1%): Insomnia, nervousness
Frequency not reported: Abnormal dreams, depression, hallucinations, mood changes (including depression), personality change
There were rare cases of clinical hepatitis that were reversible with discontinuation of this drug.
Uncommon (0.1% to 1%): Increased hepatic enzymes (ALT, AST)
Frequency not reported: Clinical hepatitis/hepatitis
Frequency not reported: Eosinophilia, hemolytic anemia, increased bleeding time, leukopenia, lymphadenopathy, thrombocytopenia
Postmarketing reports: Purpura
Frequency not reported: Allergic reactions, angioedema (including facial/periorbital edema)
Frequency not reported: Gynecomastia
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Matzim La